相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Factors Associated with Higher Body Mass Index, Weight Concern, and Weight Gain in a Multinational Cohort Study of Smokers Intending to Quit
Henri-Jean Aubin et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2009)
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence:: insights from pre-clinical and clinical studies
Bernard Le Foll et al.
ADDICTION BIOLOGY (2008)
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Mark J. Eisenberg et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2008)
Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats
Laura Lamota et al.
NEUROPHARMACOLOGY (2008)
Joint effects of tobacco use and body mass on all-cause mortality in Mumbai, India: Results from a population-based cohort study
Mangesh S. Pednekar et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen et al.
LANCET (2007)
Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial
David Gonzales et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Investigating the factor structure of the Questionnaire on Smoking Urges-Brief (QSU-Brief)
Benjamin A. Toll et al.
ADDICTIVE BEHAVIORS (2006)
Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice
GN Balerio et al.
PSYCHOPHARMACOLOGY (2006)
Varenicline:: An α4β2 nicotinic receptor partial agonist for smoking cessation
JW Coe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Smoking cessation, lung function, and weight gain:: a follow-up study
S Chinn et al.
LANCET (2005)
Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial
GD Smith et al.
ANNALS OF INTERNAL MEDICINE (2005)
Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
SA Doggrell
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
How does bupropion work as a smoking cessation aid?
C Warner et al.
ADDICTION BIOLOGY (2005)
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)
C Cohen et al.
NEUROPSYCHOPHARMACOLOGY (2005)
SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor:: Biochemical and pharmacological characterization
M Rinaldi-Carmona et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine
S González et al.
BRAIN RESEARCH (2002)
分享论文
